Skip to main content
. Author manuscript; available in PMC: 2012 Mar 3.
Published in final edited form as: Vaccine. 2011 Jan 15;29(11):2011–2014. doi: 10.1016/j.vaccine.2011.01.001

Table 2.

SEAP-NA antibody titer correlations, sequence identity, and vaccine efficacy between HPV vaccine-related and cross types (Month 12).

Vaccine-
related Type		 Vaccine-
cross Type		 Vaccine Efficacy
(96.1% CI)a 		Vaccine-
cross Type
Identity to
HPV16 (%)c 		Vaccine-
cross Type
Identity to
HPV18 (%)c 		N Spearman
(ρ) (p-value)
HPV16 HPV31 79% (70.2-85.2) b 83 66 46 0.54 0.0001
HPV52 7.8% (−8.7-21.8) 80 66 46 0.05 0.76
HPV58 1.8% (−26.0-23.4) 80 66 46 −0.24 0.11
HPV18 HPV45 76% (60.4-85.7) b 67 88 46 0.31 0.04
a

- Vaccine efficacy (6-month persistent infection) results from Paavonen et. al, Lancet 2009; 374: 301–14.

b

- Vaccine efficacy was only significant (p<0.0001) for these vaccine cross-types.

c

- HPV vaccine-cross type amino acid identity results were obtained from Brown et. al, JID 2009; 199:926 –35.